Health News Releases

13:10

QPS Holdings, LLC divests its Neuropharmacology Business Unit

Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a

11:50

Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development

November 30, 15:36

Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines

Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL - frown lines) and lateral canthal lines (LCL - crow’s fe

November 30, 15:15

ReValve Solutions Announces Successful First-in-Human with Next Generation TMVR Technology

ReValve Solutions Inc. (ReValve), which has developed a next generation technology for Transcatheter Mitral Valve Replacement (TMVR), announced that an 81-year-old male, with a history of heart failur

November 29, 13:50

Healthcare Leaders Cite Automation, Worker Burnout as Top Drivers of Technology Integrations, MGMA and Laserfiche Study Finds

New research by Medical Group Management Association (MGMA) and Laserfiche (https://www.laserfiche.com/?utm_content=mgma2023&utm_campaign=healthcare) — the leading SaaS provider of intelligent content

November 29, 11:50

Kenvue to Participate in the Morgan Stanley Global Consumer & Retail Conference on December 6, 2023

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced the company’s participation in Morgan Stanley’s Global Consumer & Retail Conferen

November 28, 13:20

Kirin iMUSE Immune Care and Healthya Visceral Fat Down will go on sale on Tuesday, November 28!

Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday). This product is a colla

November 27, 09:00

APR Achieves Consolidated Sales of KRW 122 Billion and Consolidated Operating Profit of KRW 21.7 Billion in Q3 2023

APR Corp. (https://www.apr-in.com/) (APR, CEO: Byunghoon Kim), a global beauty tech company, broke its record-high performance in Q3 2023. APR disclosed on November 14 that it had consolidated sal

November 26, 13:59

Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats

Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for SENVELGO® (active ingredient: velagliflozin), marking a significant step f

November 26, 13:36

Japan’s First Discovery*1 on Visceral Fat and Immune Activity in Joint Research by Kirin Holdings and Kao

Kirin Holdings Company, Limited (TOKYO:2503) and Kao Corporation (TOKYO:4452) will participate in the Wakayama Health Promotion Study, a cohort study*2 led by Wakayama Medical University and organized

November 23, 09:50

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma ha

November 22, 10:40

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from

November 21, 16:35

Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories

Galderma: ·Galderma achieved net sales of 3,009 M USD over the first nine months of 2023, up 8.9% year-on-year on a constant currency basis ·Continued pipeline progress with new milestones reached

November 19, 12:41

MicroVention Celebrates 10-Year Anniversary and Legacy of SOFIA™ Aspiration Catheters; More than 500,000 Procedures Performed Worldwide Across 170 Countries

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, is celebrating a decade of legacy innovation commemorating the anniversary of SOFIA™ and SOFIA™ Fl

November 19, 11:19

Morinaga Milk’s Probiotic Bifidobacterium breve B-3 Receives Approval of Individual Recognized Registration in South Korea

Morinaga Milk Industry Co., Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.morinagamilk.co.jp%2Fenglish%2F&esheet=53837044&newsitemid=20231116301397&lan=en-US&anchor=Morina

November 17, 17:15

Evidation Selected by Our Future Health as Participant Platform for UK’s Largest Health Research Program

Evidation (https://evidation.com/) — the company creating new ways to measure and improve health in everyday life — today announced a landmark partnership with Our Future Health (https://ourfutureheal

November 17, 11:30

SMK Entered into Capital and Business Alliance Agreement with Canary Speech (US)

SMK Corporation (TOKYO: 6798) (https://www.smk.co.jp/) (President, CEO and COO: Yasumitsu Ikeda, hereinafter referred to as SMK) announced that it has entered into a capital and business alliance agre

November 15, 11:30

Ketamine Clinic in Japan for Inbound Medical Treatment: Nagoya Anesthesia Clinic

Nagoya Anesthesia Clinic (https://nagoyamasui.com/2-2), located in Nagoya City, Aichi Prefecture, Japan, has initiated inbound medical treatment for treatment-resistant depression, other mental disord

November 12, 11:00

GenScript ProBio Signs Viral Vector Manufacturing MOU With Curocell for Next-Generation CAR-T Therapy

On November 10, a global multimodality CDMO, GenScript ProBio and specialized CAR-T therapy firm Curocell signed a strategic partnership MOU for the production of viral vectors necessary for the devel

November 10, 17:40

Takeda Receives U.S. FDA Approval of FRUZAQLA™ for Previously Treated Metastatic Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy

November 10, 12:00

GenScript ProBio Partners With NuclixBio to Pave the Way for South Korea’s First Large-scale Production Process for ‘Circular RNA Therapeutics’

GenScript ProBio, a global multimodality CDMO and NuclixBio, a company developing treatments based on circular RNA, announced on 9th Nov that they have entered into a strategic business agreement to d

November 10, 11:15

Takeda’s ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura

Takeda (https://www.takeda.com/) (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recom

November 10, 10:35

Aster Guardians Global Nursing Award 2024 Worth $250,000 to be Held in Bengaluru, India; Application Deadline Extended till 15th December

Aster Guardians Global Nursing Award 2024, an initiative by leading integrated healthcare provider Aster DM Healthcare, has extended the submission deadline to December 15th, 2023. Due to an overwhelm

November 09, 10:15

Confluent Medical Sees Dramatic Improvements Around Supply Chain Visibility and Efficiency

Confluent Medical, a leading materials science, development and manufacturing partner to medical device manufacturers (“OEMs”), has experienced significant improvements to its end-to-end supply chain

November 09, 09:50

Pharma Leader Dr. Holger Zimmermann Joins Lysando's Advisory Board in Pioneering Fight Against Antibiotic-Resistant Bacteria

Lysando, a leading innovator in the fight against antibiotic-resistant bacteria, proudly announces the appointment of Dr. Holger Zimmermann to its Advisory Board. Dr. Zimmermann‘s distinguished career

News by Region

News by Industry